Straits Times Index
3,098.25 +56.96 (+1.87%) S&P 500
4,567.00 -88.27 (-1.90%) Dow
34,483.72 -652.22 (-1.86%) Nasdaq
15,537.69 -245.14 (-1.55%) BTC-USD
57,084.14 +576.44 (+1.02%) CMC Crypto 200
1,470.27 +27.49 (+1.91%)
Organon & Co. (OGN)
After hours:
- Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2021
JERSEY CITY, N.J., November 11, 2021--Organon (NYSE: OGN) (the "company"), today announced its results for the third quarter and year to date ended September 30, 2021.
- Business Wire
Organon to Acquire Forendo Pharma
JERSEY CITY, N.J. & TURKU, Finland, November 11, 2021--Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral
- CNW Group
NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary
Organon (NYSE: OGN) is pleased to announce NEXPLANON® (etonogestrel extended-release subdermal implant) public listing in Quebec under the Régie de l'assurance maladie du Québec (RAMQ) as of November 10. NEXPLANON® is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1 Quebec is the fifth jurisdiction to list NEXPLANON® on its public formulary, including the Non-Insured Health Benefits program, Veterans Affairs Canada and the Saskatchewan Drug Plan.
